![](https://endpts.com/wp-content/uploads/2024/04/Joaquin-Duato-JJ-Johnson-Johnson-AP-tile.jpg)
Joaquin Duato, J&J CEO (Jacquelyn Martin/AP Images)
J&J’s multiple myeloma therapies drive oncology business despite slow Carvykti sales
Johnson & Johnson defended slower-than-expected sales of Carvykti in the first quarter, with execs saying they expect sales of the cell therapy to accelerate in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.